1. Community Update
2. Rare Disease Day
3. Development Program Update
4. Expanded Access Program

Community Update

Recently, Mandos attended the 2023 INPDA Face to Face meeting in Tarragona Spain November 10-12, 2023, which was hosted by Fundación Niemann Pick de Espan᷉a. The meeting demonstrated the incredible progress of the NPC community. Over one hundred attendees representing NPC research, foundations, industry, caregivers, and families attended the conference. HOPE WINS was the conference theme in honor of those who have lost their battle with NPC disease.

Mandos was proud to support and connect with all facets of the NPC community to advance the research and development of adrabetadex (VTS-270) for patients living with NPC.

INPDA 2023, Tarragona, Spain

Mandos will be attending and sponsoring the 2024 Parseghian Fund Annual Conference on June 8-11, 2024 in Tucson, AZ, and the NNPDF Family Support & Medical Conference on July 11 – 13 in Salt Lake City, Utah.

Rare Disease Day

Mandos Health is excited to participate in Rare Disease Day 2024!

We will be sharing our colors and participating in patient speaker series and patient stories to help raise awareness and educate our teams about generating change for the 300 million people worldwide living with a rare disease, their families and carers.

Rare Disease Day this year is on Thursday, February 29th.

Development Program Update

We continue to drive forward our plans to support a laser-focused evaluation of clinical, biomarker, natural history, and real-world data for the VTS program. This analysis will be the first of its kind in NPC.

We are getting closer to finishing our assessment and we intend to begin writing publications and sharing our data findings with the NPC community and thought leaders after we receive advice from the regulatory agencies.

We know every day matters. We couldn’t be more grateful for the trust you continue to place in us.

Expanded Access Program (EAP) Update

We remain steadfast in our commitment to the EAP. Recently, we invested in securing an additional drug product manufacturing site which allows continued supply of VTS-270 through 2025.

Mandos Health would also like to thank those sites who continue to provide expanded access and care to the NPC patients and their families.

Stay up to date with our progress

We are committed to continuing to build a science-driven organization dedicated to NPC.

We enjoy engaging all stakeholders with updated communications through conference attendance and patient advocacy organization meetings.

Stay up to date with us at www.mandoshealth.com